These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35850480)

  • 21. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.
    Berger R; Zhu C; Hansen AR; Harper B; Chen Z; Holt TG; Hubert J; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; Wolff M; Macneil DJ; Weber AE; Edmondson SD
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4833-7. PubMed ID: 18684621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen.
    Burford NT; Wehrman T; Bassoni D; O'Connell J; Banks M; Zhang L; Alt A
    J Biomol Screen; 2014 Oct; 19(9):1255-65. PubMed ID: 25047277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New screening strategy and analysis for identification of allosteric modulators for glucagon-like peptide-1 receptor using GLP-1 (9-36) amide.
    Nakane A; Gotoh Y; Ichihara J; Nagata H
    Anal Biochem; 2015 Dec; 491():23-30. PubMed ID: 26341912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of Positive Allosteric Modulators of the D
    Luderman KD; Conroy JL; Free RB; Southall N; Ferrer M; Sanchez-Soto M; Moritz AE; Willette BKA; Fyfe TJ; Jain P; Titus S; Hazelwood LA; Aubé J; Lane JR; Frankowski KJ; Sibley DR
    Mol Pharmacol; 2018 Oct; 94(4):1197-1209. PubMed ID: 30068735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression.
    Wan Y; Deng Q; Zhou Z; Deng Y; Zhang J; Li J; Wang Y
    Poult Sci; 2023 Jan; 102(1):102273. PubMed ID: 36436379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for design of non peptide CCK1R agonist/antagonist ligands.
    García-López MT; González-Muñiz R; Martín-Martínez M; Herranz R
    Curr Top Med Chem; 2007; 7(12):1180-94. PubMed ID: 17584140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benzodiazepine ligands can act as allosteric modulators of the Type 1 cholecystokinin receptor.
    Gao F; Sexton PM; Christopoulos A; Miller LJ
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4401-4. PubMed ID: 18621527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different downstream signalling of CCK1 receptors regulates distinct functions of CCK in pancreatic beta cells.
    Ning SL; Zheng WS; Su J; Liang N; Li H; Zhang DL; Liu CH; Dong JH; Zhang ZK; Cui M; Hu QX; Chen CC; Liu CH; Wang C; Pang Q; Chen YX; Yu X; Sun JP
    Br J Pharmacol; 2015 Nov; 172(21):5050-67. PubMed ID: 26248680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CCK1R agonists: a promising target for the pharmacological treatment of obesity.
    Szewczyk JR; Laudeman C
    Curr Top Med Chem; 2003; 3(8):837-54. PubMed ID: 12678836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual-agonist occupancy of orexin receptor 1 and cholecystokinin A receptor heterodimers decreases G-protein-dependent signaling and migration in the human colon cancer cell line HT-29.
    Bai B; Chen X; Zhang R; Wang X; Jiang Y; Li D; Wang Z; Chen J
    Biochim Biophys Acta Mol Cell Res; 2017 Jul; 1864(7):1153-1164. PubMed ID: 28288880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.
    Desai AJ; Dong M; Miller LJ
    Clin Nutr; 2016 Dec; 35(6):1374-1379. PubMed ID: 27016394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe.
    Laprairie RB; Kulkarni AR; Kulkarni PM; Hurst DP; Lynch D; Reggio PH; Janero DR; Pertwee RG; Stevenson LA; Kelly ME; Denovan-Wright EM; Thakur GA
    ACS Chem Neurosci; 2016 Jun; 7(6):776-98. PubMed ID: 27046127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of interaction of phenolic compounds with the cholecystokinin signaling pathway to explain effects on reducing food intake.
    Al Shukor N; Raes K; Van Camp J; Smagghe G
    Peptides; 2014 Mar; 53():225-31. PubMed ID: 24630973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.
    Dong M; Vattelana AM; Lam PC; Orry AJ; Abagyan R; Christopoulos A; Sexton PM; Haines DR; Miller LJ
    Mol Pharmacol; 2015 Jan; 87(1):130-40. PubMed ID: 25319540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structures of the human cholecystokinin 1 (CCK1) receptor bound to Gs and Gq mimetic proteins provide insight into mechanisms of G protein selectivity.
    Mobbs JI; Belousoff MJ; Harikumar KG; Piper SJ; Xu X; Furness SGB; Venugopal H; Christopoulos A; Danev R; Wootten D; Thal DM; Miller LJ; Sexton PM
    PLoS Biol; 2021 Jun; 19(6):e3001295. PubMed ID: 34086670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validated ligand binding sites in CCK receptors. next step: computer-aided design of novel CCK ligands.
    Tikhonova IG; Marco E; Lahlou-Archer E; Langer I; Foucaud M; Maigret B; Fourmy D
    Curr Top Med Chem; 2007; 7(12):1243-7. PubMed ID: 17584146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
    Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of tyrosine 189 and asparagine 358 of the cholecystokinin 2 receptor in direct interaction with the crucial C-terminal amide of cholecystokinin by molecular modeling, site-directed mutagenesis, and structure/affinity studies.
    Galés C; Poirot M; Taillefer J; Maigret B; Martinez J; Moroder L; Escrieut C; Pradayrol L; Fourmy D; Silvente-Poirot S
    Mol Pharmacol; 2003 May; 63(5):973-82. PubMed ID: 12695525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
    Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
    J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.